{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:10:41Z","timestamp":1784556641157,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.ijrobp.2003.12.013","type":"journal-article","created":{"date-parts":[[2004,7,2]],"date-time":"2004-07-02T18:52:12Z","timestamp":1088794332000},"page":"1148-1156","source":"Crossref","is-referenced-by-count":23,"title":["Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Vassilios E.","family":"Kouloulias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Kouvaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Kokakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Kostakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Mallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Metafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros J.","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2003.12.013_BIB1","series-title":"Radiation sensitizers","first-page":"209","article-title":"Biological characteristics of some improved radioprotectors","author":"Davidson","year":"1980"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB2","first-page":"1","article-title":"The current status of WR-2721 (amifostine)","volume":"3","author":"Schuchter","year":"1993","journal-title":"Biologic Ther Cancer"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.1988.6.4.709","article-title":"Chemical modifiers of cancer treatment","volume":"6","author":"Coleman","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB4","first-page":"3634","article-title":"Uptake of amifostine derivatives by cells in culture","volume":"48","author":"Calabro-Jones","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0167-8140(00)00235-8","article-title":"Has the outlook improved for amifostine as a clinical radioprotector?","volume":"57","author":"Lindegaard","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB6","first-page":"1519","article-title":"Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid","volume":"40","author":"Yuhas","year":"1980","journal-title":"Cancer Res"},{"issue":"Suppl. 4","key":"10.1016\/j.ijrobp.2003.12.013_BIB7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0959-8049(96)00333-4","article-title":"The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol)","volume":"32A","author":"Capizzi","year":"1996","journal-title":"Eur J Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.ijrobp.2003.12.013_BIB8","first-page":"2","article-title":"Amifostine","volume":"23","author":"Capizzi","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB9","first-page":"189","article-title":"Amifostine","volume":"5","author":"McCauley","year":"1997","journal-title":"Cancer Pract"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0360-3016(82)90684-8","article-title":"Clinical trials of WR-2721 with radiation therapy","volume":"8","author":"Blumberg","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00066-003-0970-y","article-title":"Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors","volume":"179","author":"Kouvaris","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB12","first-page":"458","article-title":"The cytoprotective effect of amifostine in acute radiation dermatitis","volume":"12","author":"Kouvaris","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000066055","article-title":"Cytoprotective effect of amifostine in radiation-induced acute mucositis retrospective analysis","volume":"25","author":"Kouvaris","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB14","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1200\/JCO.1999.17.10.3333","article-title":"American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants","volume":"17","author":"Hensley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB15","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0360-3016(86)90203-8","article-title":"Human pharmacokinetics of WR-2721","volume":"12","author":"Shaw","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl. 4","key":"10.1016\/j.ijrobp.2003.12.013_BIB16","first-page":"S26","article-title":"Amifostine (Ethyol)","volume":"32A","author":"van der Vijgk","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB17","series-title":"Handbook for reporting results of cancer treatment","year":"1979"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria, version 2.0","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB19","unstructured":"Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria, Appendix B. http:\/\/www.rtog.org\/members\/toxicity\/main.html"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB20","first-page":"69","article-title":"Management of pituitary adenomas","volume":"66","author":"Leavens","year":"1992","journal-title":"Oncology (Huntngtn)"},{"issue":"Suppl. 4","key":"10.1016\/j.ijrobp.2003.12.013_BIB21","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0959-8049(96)00328-0","article-title":"Amifostine (Ethyol)","volume":"32A","author":"Bukowski","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB22","series-title":"Nonparametric statistics for the behavioral sciences","author":"Siegel","year":"1988"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB23","series-title":"Applied logistic regression","author":"Hosmer","year":"1989"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0360-3016(86)90203-8","article-title":"Human pharmacokinetics of WR-2721","volume":"12","author":"Shaw","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0163-7258(88)90061-7","article-title":"Pharmacokinetics of WR-2721","volume":"39","author":"Shaw","year":"1988","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB26","first-page":"895","article-title":"Metabolic pathway of WR-2721 (Ethyol, amifostine) in the BALB\/c mouse","volume":"22","author":"Shaw","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0163-7258(88)90061-7","article-title":"Pharmacokinetics of WR2721","volume":"39","author":"Shaw","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/0360-3016(84)90495-4","article-title":"Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721","volume":"10","author":"Utley","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazards of accelerated tumour clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2307\/3576436","article-title":"Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913)","volume":"102","author":"Rasey","year":"1985","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/09553009214551291","article-title":"Topical or systemic 16, 16dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation","volume":"61","author":"Geng","year":"1992","journal-title":"Int J Radiat Biol"},{"issue":"Suppl. 11","key":"10.1016\/j.ijrobp.2003.12.013_BIB32","first-page":"21","article-title":"Radiotherapeutic studies with amifostine (Ethyol)","volume":"21","author":"Wasserman","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/0360-3016(94)00423-I","article-title":"Pathophysiology of irradiated skin and breast","volume":"31","author":"Archambeau","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB34","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/0360-3016(86)90132-X","article-title":"Influence of WR 2721 on radiation response of canine soft tissue sarcomas","volume":"12","author":"McChesney","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB35","first-page":"2261","article-title":"Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts","volume":"12","author":"Treskes","year":"1992","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB36","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities","volume":"14","author":"Kemp","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0360-3016(92)90527-O","article-title":"Interim analysis of a randomized trial of radiation therapy of rectal cancer with\/without WR-2721","volume":"22","author":"Kligerman","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB38","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/1097-0142(19920601)69:11<2820::AID-CNCR2820691130>3.0.CO;2-T","article-title":"Use of radiation with or without WR-2721 in advanced rectal cancer","volume":"69","author":"Liu","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2003.12.013_BIB39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0163-7258(88)90059-9","article-title":"Radioprotectors in tumor radiotherapy","volume":"39","author":"Milas","year":"1988","journal-title":"Pharmacol Ther"},{"issue":"Suppl. 8","key":"10.1016\/j.ijrobp.2003.12.013_BIB40","first-page":"40","article-title":"Guidelines for the administration of amifostine","volume":"23","author":"Schuchter","year":"1996","journal-title":"Semin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030160302443X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030160302443X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T07:52:02Z","timestamp":1549439522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030160302443X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S036030160302443X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2003.12.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}